---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-26-000045"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2026-09-03T20:18:54+00:00"
generated_at: "2026-09-03T20:21:26.552502+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte appoints CMO and CLO; narrows VAX-31 OPUS-1 topline data to end of October 2026

## Summary
- Luis Jodar, Ph.D., former Pfizer CMO for Vaccines and Infectious Diseases, joins as Chief Medical Officer.
- David McAvoy, J.D., former Teva Chief Legal Officer, joins as Chief Legal Officer; Mikhail Eydelman remains SVP, General Counsel.
- Topline safety, tolerability, and immunogenicity data from VAX-31 Phase 3 OPUS-1 trial now expected by end of October 2026, narrowing prior Q4 guidance.
- Jodar led clinical development and medical affairs for Prevnar 13 and Prevnar 20 at Pfizer.

## SEC filing metadata
- accession: 0001649094-26-000045
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2026-09-03T20:18:54+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/0001649094-26-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/pcvx-20260831.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-26-000045
- JSON: https://secwatch.observer/filing/0001649094-26-000045.json
- Plain text: https://secwatch.observer/filing/0001649094-26-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.